ReachMDDriving Progress in Cardiology: Exploring the Role of FXI in Acute Coronary Syndromes & Beyond 

This CME content reflects expert opinion and early-phase data, not yet peer-reviewed outcomes.

Factor XI inhibition is emerging as a potential strategy to reduce thrombosis without increasing bleeding risk, addressing a critical gap in post-ACS management. A phase 3 trial of milvexian, a selective FXI inhibitor, has enrolled more than 10,000 ACS patients on background DAPT, with results pending.

Clinical Considerations

• Human genetic data shows FXI-deficient individuals have lower rates of MI, stroke, and VTE with minimal spontaneous bleeding, providing the biological rationale for FXI inhibition.
• Thrombin remains the most potent platelet activator, yet current antiplatelet agents including aspirin, ticagrelor, and prasugrel do not block thrombin-mediated platelet aggregation.
• Prior dual pathway inhibition trials (ATLAS, COMPASS) demonstrated mortality reduction but unacceptable bleeding, driving interest in FXI as a safer alternative target.
• Earlier FXI inhibitor asundexian failed in the AF setting (OCEANIC-AF), with investigators attributing the result to suboptimal once-daily dosing and inadequate trough levels.

Practice Applications

• Monitor milvexian and abelacimab trial results before incorporating FXI inhibition into post-ACS or AF anticoagulation decisions.
• Reassess DAPT duration for high bleeding risk patients: meta-analysis of 11 trials shows shorter DAPT reduces bleeding without increasing ischemic risk.
• Eliminate aspirin in favor of ticagrelor monotherapy after a short DAPT course in eligible post-PCI patients per 2025 ACC guidance.
• Target LDL below 55 mg/dL in post-ACS patients; experts note this benchmark is frequently missed in clinical practice.

More in Anticoagulation Management